# KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

> **NCT03848286** · PHASE2 · COMPLETED · sponsor: **Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.** · enrollment: 153 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma
- Recurrent or Metastatic

## Interventions

- **DRUG:** KL-A167 Injection

## Key facts

- **NCT ID:** NCT03848286
- **Lead sponsor:** Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-06
- **Primary completion:** 2021-07-13
- **Final completion:** 2022-01-13
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03848286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03848286, "KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03848286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*